Syros Pharmaceuticals Inc (0S90.SG)
Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
As of 08:21AM CEST. Market open.
| Previous close | 4.5600 |
| Open | 4.6000 |
| Bid | 4.6000 x N/A |
| Ask | 4.8200 x N/A |
| Day's range | 4.6000 - 4.6000 |
| 52-week range | 1.9600 - 7.2600 |
| Volume | |
| Avg. volume | 1 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GuruFocus.com
Syros Pharmaceuticals Inc (SYRS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
Explore key updates on clinical trials, financial shifts, and strategic insights from Syros Pharmaceuticals' Q1 2024 earnings call.
- Thomson Reuters StreetEvents
Q1 2024 Syros Pharmaceuticals Inc Earnings Call
Q1 2024 Syros Pharmaceuticals Inc Earnings Call
Business WireSyros Reports First Quarter 2024 Financial Results and Provides a Corporate Update
CAMBRIDGE, Mass., May 14, 2024--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended March 31, 2024 and provided a corporate update.
© 2024 Yahoo. All rights reserved.